<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24926632</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>09</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>06</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0040-5957</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>69</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Season>Mar-Apr</Season>
            </PubDate>
          </JournalIssue>
          <Title>Therapie</Title>
          <ISOAbbreviation>Therapie</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Baclofen and liver cirrhosis: literature review and safety precautions implemented within the system CAMTEA].</ArticleTitle>
        <Pagination>
          <StartPage>143</StartPage>
          <EndPage>147</EndPage>
          <MedlinePgn>143-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2515/therapie/2013072</ELocationID>
        <Abstract>
          <AbstractText>The off-label prescribing of high dose baclofen (HDB) has been recently spreading in France. The impact of HDB on subjects with liver cirrhosis remains poorly known. The main pharmacodynamic and pharmacokinetic data on baclofen result from studies on healthy subjects or using low doses of treatment. The specific biodisponibility and elimination of HDB have not been studied yet in cirrhosis. National pharmacovigilance reports suggest that a careful use of baclofen or even HDB could be possible in compensated cirrhosis. However, theoretical risks of baclofen overdose exist in cases of hepatorenal syndrome or portosystemic shunt. Baclofen could also induce a specific pharmacological potentiation of hepatic encephalopathy and gastropathy. Within CAMTEA, a regional team-based multidisciplinary system for delivering and monitoring off-label medications in alcohol use disorders, a set of predefined precautions for using baclofen in cirrhosis have been implemented, until further information becomes available. These precautions notably consist of a protocolized process for declaring adverse events, and a hepatologic follow-up associated with the usual multidisciplinary care system set up within CAMTEA.</AbstractText>
          <CopyrightInformation>© 2014 Société Française de Pharmacologie et de Thérapeutique.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rolland</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Dispositif CAMTEA, CHU Lille, Lille, France - Service d'Addictologie, CHU Lille, Lille, France - Université Lille Nord de France, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deheul</LastName>
            <ForeName>Sylvie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dispositif CAMTEA, CHU Lille, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Louvet</LastName>
            <ForeName>Alexandre</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Service de Gastro-entérologie, CHU Lille, Lille, France - Université Lille Nord de France, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gautier</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Service de Pharmacovigilance, CHU Lille, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cottencin</LastName>
            <ForeName>Olivier</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Dispositif CAMTEA, CHU Lille, Lille, France - Service d'Addictologie, CHU Lille, Lille, France - Université Lille Nord de France, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bordet</LastName>
            <ForeName>Régis</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Dispositif CAMTEA, CHU Lille, Lille, France - Université Lille Nord de France, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>le dispositif CAMTEA</CollectiveName>
          </Author>
        </AuthorList>
        <Language>fre</Language>
        <PublicationTypeList>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Baclofène et cirrhose : analyse de la littérature et précautions d'emploi adoptées au sein du dispositif CAMTEA.</VernacularTitle>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>06</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Therapie</MedlineTA>
        <NlmUniqueID>0420544</NlmUniqueID>
        <ISSNLinking>0040-5957</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058786">GABA-B Receptor Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H789N3FKE8</RegistryNumber>
          <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058786" MajorTopicYN="N">GABA-B Receptor Agonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006501" MajorTopicYN="N">Hepatic Encephalopathy</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033183" MajorTopicYN="N">Interdisciplinary Communication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056687" MajorTopicYN="Y">Off-Label Use</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName>
          <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
          <QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24926632</ArticleId>
        <ArticleId IdType="doi">10.2515/therapie/2013072</ArticleId>
        <ArticleId IdType="pii">th132187</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
